Find Clinical Drug Pipelines for Trauma (Emergency, Injury, Surgery)

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type Full Screen

            Development Status Full Screen

            Virtual BoothDevelopment, Manufacturing & Marketing of Pharmaceuticals for Central Nervous System Pathologies.

            Contact the Supplier

            Lead Product(s): Cannabis products

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Panaxia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 22, 2020

            Details:

            The agreement, which anchors a previous MOU entered by the companies, includes exclusivity for Panaxia products, as well as an option for scaling the distribution to additional countries, also including further major European countries.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Wnt Activating Antibodies

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Surrozen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 29, 2020

            Details:

            Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dextrans

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ILB

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 14, 2020

            Details:

            The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxypurinol

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            This filing initiates formal communications with the U.S. FDA regarding development of the Company’s proprietary formulation of XRx-101 (Oxypurinol) for the treatment and prevention of acute kidney injury (AKI) associated with COVID-19 coronavirus infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BA-1049

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BA-1049

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 28, 2020

            Details:

            The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 3,4-Methylenedioxymethamphetamine

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            EmpathBio, a wholly-owned subsidiary of ATAI Life Sciences is developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder (PTSD) and other indications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TRV027

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: TRV027

            Highest Development Status: Phase I Product Type: Peptide

            Partner/Sponsor/Collaborator: Imperial College London

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AV-001

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: AV-001

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: US Department of Defense

            Deal Size: $2.8 million Upfront Cash: Undisclosed

            Deal Type: Funding August 18, 2020

            Details:

            Funding will support the development AV-001 for the treatment of COVID-19-associated acute lung injury and acute respiratory distress syndrome (ARDS).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): StrataGraft skin tissue

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 10, 2020

            Details:

            U.S. Food and Drug Administration has accepted for review the Stratatech Biologics License Application (BLA) for StrataGraft®, an investigational regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Oxypurinol

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: XRx-101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Icahn School of Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 04, 2020

            Details:

            XRx-101 is a proprietary of xanthine oxidase inhibitor oxypurinol. The study provides clues about the potential of XRx-101 as a treatment to suppress the severity of the coronavirus / COVID-19 infection.

            PharmaCompass